A Bridge To The Future: Our World-Class Site In Bridgeton

Rising demand for biologics, GLP‑1 therapies, and other sterile injectables is reshaping the expectations placed on modern manufacturing sites. Bridgeton stands out as a purpose-built facility designed to manage this growing complexity with speed, precision, and end-to-end integration.

Its expansive cGMP‑compliant footprint brings formulation, aseptic fill finish, assembly, and final packaging together under one roof, reducing the risks commonly introduced when multiple vendors handle different stages of production. Four high‑speed filling lines support vials, cartridges, and prefilled syringes, each equipped with isolator technology, inert environments, and real‑time process controls that help maintain sterility, accuracy, and regulatory alignment. The site’s scale — capable of producing more than 150 million units annually — offers the flexibility required for clinical batches through full commercial launch, while additional cleanroom space and digital‑first design principles ensure long‑term adaptability.

With capabilities spanning controlled‑substance handling, advanced emergency‑preparedness projects, and integrated quality oversight, Bridgeton provides a streamlined pathway for delivering complex injectable therapies to patients efficiently and reliably. Access the full eBook to explore how an integrated site model can de‑risk development and accelerate time to market.